Now that we have a direct renin inhibitor, what should we do with it?

Current Hypertension Reports

Volumn 10, Issue 3, 2008, Pages 194-200

  Stanton, Alice ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; AMINOPYRIDINE DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ASPARTIC PROTEINASE INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; PLACEBO; RAMIPRIL; RENIN; RENIN INHIBITOR; SPP 1148; SPP 635; UNCLASSIFIED DRUG;

CATALYST; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EUROPE; GENOTYPE; HUMAN; MONOTHERAPY; MORBIDITY; MORTALITY; NONHUMAN; PRESCRIPTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; UNITED STATES; UNSPECIFIED SIDE EFFECT;

AMIDES; ANTIHYPERTENSIVE AGENTS; FUMARATES; HUMANS; HYPERTENSION; RECEPTORS, CELL SURFACE; RENIN; RENIN-ANGIOTENSIN SYSTEM; VACUOLAR PROTON-TRANSLOCATING ATPASES;

EID: 56349167105     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-008-0037-7     Document Type: Review

References (56)

1. Oparil S, Haber E: The renin-angiotensin system. N Engl J Med 1974, 291:381-401, 446-457.
2. Dzau VJ: Tissue angiotensin and pathobiology of vascular disease, a unifying hypothesis. Hypertension 2001, 37:1047-1052.
3. Matchar DB, McCrory DC, Orlando LA, et al.: Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 2008, 148:16-29.
4. SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325:293-302.
5. Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709-717.
6. Cohn JN, Tognoni G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667-1675.
7. Campbell DJ, Aggarwal A, Esler M, Kaye D: Beta-blockers. angiotensin II, and ACE inhibitors in patients with heart failure. Lancet 2001, 358:1609-1610.
8. Kunz R, Friedrich C, Wolbers M, Mann JF: Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease. Ann Intern Med 2008, 148:30-48.
9. Beta Blocker Heart Attack Trial Research Group: A randomized trial of propranolol in patients with acute myocardial infarction: mortality results. JAMA 1982, 247:1707.
10. Yusef S, Sleight P, Pogue J, et al.: Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145-153.
11. Dahlof B, Devereux RB, Kjeldsen SE, et al.; the LIFE study group: Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995-1003.
12. Rahuel J, Rasetti V, Maibaum J, et al.: Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Chem Biol 2000, 7:493-504.
13. Wood JM, Maibaum J, Rahuel J, et al.: Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003, 308:698-705.
14. Speedel Direct Renin Inhibitor Pipeline. Available at http://www.speedel.com/section/4/subsections/0. Accessed January 15, 2008.
15. Actelion Renin Inhibitor in Clinical Development. Available at http://www.actelion.com/uninet/www/wwwi_man_p.nsf/Content/ Renin+Inhibitor+in+Clinical+Development. Accessed January 15, 2008.
16. Vitae Pharmaceuticals Product Pipeline. Available at http://www.vitaepharma.com./pipeline/index.php. Accessed January 15, 2008.
17. Sarver RW, Peevers J, Cody WL, et al.: Binding thermodynamics of substituted diaminopyrimidine renin inhibitors. Anal Biochem 2007, 360:30-40.
18. Wood JM, Schnell CR, Cumin F, et al.: Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J Hypertens 2005, 23:417-426.
19. Rigel DF, Fu F, Li S, et al.: The renin inhibitor is a potent and long-acting antihypertensive in double transgenic rats expressing human renin and angiotensinogen genes [abstract]. J Am Coll Cardiol 2004, 43:483A.
20. Pilz B, Shagdasuren E, Wellner M, et al.: Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 2005, 46:569-576.
21. Mazzolai L, Korber M, Aubert JF, et al.: Renin inhibitor, aliskiren, prevents vulnerable plaque development in a mouse model of unstable plaque [abstract]. Eur Heart J 2005, 26(Suppl):296.
22. Nussberger J, Wuerzner G, Jensen C, Brunner HR: Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension 2002, 39:E1-E8.
23. Stanton A, Jensen C, Nussberger J, O'Brien E: Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003, 42:1137-1143.
24. Gradman AH, Schmieder RE, Lins RL, et al.: Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005, 111:1012-1018.
25. Uresin Y, Taylor AA, Kilo C, et al.: Aliskiren, a novel renin inhibitor, has greater BP lowering than ramipril and additional BP lowering when combined with ramipril in patients with diabetes and hypertension [abstract]. J Hypertens 2006, 24(Suppl 4):582.
26. Villamil A, Chrysant SG, Calhoun D, et al.: Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007, 25:217-226
27. Munger MA, Drummond W, Essop MR, et al.: Aliskiren as add-on to amlodipine provides significant additional blood pressure lowering without increased oedema associated with doubling the amlodipine dose [abstract]. Eur Heart J 2006, 25(Suppl):118.
28. O'Brien E, Barton J, Nussberger J, et al.: Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension 2007, 49:1-9.
29. Oparil S, Yarrows SA, Patel S, et al.: Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension; a randomized, double-blind trial. Lancet 2007, 370:221-229.
30. Weir MR, Bush C, Zhang J, et al.: Antihypertensive efficacy and safety of the oral renin inhibitor aliskiren in patients with hypertension: a pooled analysis [abstract]. Eur Heart J 2006, 27(Suppl):299.
31. Vaidyanathan S, Jermany J, Yeh CM, et al.: Aliskiren, a novel effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects. Brit J Clin Pharmacol 2006, 62:690-698.
32. Vaidyanathan S, Jin Y, Schiller H, Jensen C: Aliskiren, a novel oral renin inhibitor, has no interaction with cytochrome P450 isoenzymes in vitro [abstract]. Basic Clin Pharmacol Toxicol 2005, 97(suppl 1).
33. Vaidyanathan S, Valencia J, Kemp C, et al.: Lack of pharmacokinetic interactions of aliskiren, a novel direct oral renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. Int J Clin Pract 2006, 60:1343-1356.
34. Dieterle W, Corynen S, Vaidyanathan S, Mann J: Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int J Clin Pharmacol Ther 2005, 43:527-535.
35. Sealey J, Laragh JH: Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. Am J Hypertens 2007, 20:587-597.
36. Menard J, Azizi M: The difficult conception, birth and delivery of a renin inhibitor: controversies around aliskiren. J Hypertens 2007, 25:1775-1782.
37. Barlucchi L, Leri A, Dostal DE, et al.: Canine ventricular myocytes possess a renin-angiotensin system that is upregulated with heart failure. Circ Res 2001, 88:298-304.
38. Re RN: The nature of intracrine peptide hormone action. Hypertension 1999, 34:534-528.
39. Fisher NDL, Allan D, Kifor I, et al.: Responses to converting enzyme and renin inhibition: role of angiotensin II in humans. Hypertension 1994, 23:44-51.
40. Burnier M: Angiotensin II type 1 receptor blockers. Circulation 2001, 103:904-912.
41. Kerins DM, Hao Q, Vaughan DE: Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest 1995, 96:2515-2520.
42. DelliPizzi AM, Hilchey SD, Bell-Quilley CP: Natriuretic action of angio (1-7). Brit J Pharmacol 1994, 111:1-3.
43. Freeman EJ, Chisolm GM, Ferrario CM, et al.: Angiotensin-(1-7) inhibits vascular smooth muscle growth. Hypertension 1996, 28:104-108.
44. Iyer SN, Chappell MC, Averill DB, et al.: Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with lisinopril and losartan. Hypertension 1998, 31:699-705.
45. Sunman W, Sever PS: Non-angiotensin effects of angiotensin-converting enzyme inhibitors. Clinical Science 1993, 85:661-670.
46. Nguyen G, Delarue F, Burckle C, et al.: Pivotal role of the renin/ prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002, 109:1417-1427.
47. Brunner HR, Baer L, Newton MA, et al.: Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 1972, 286:441-449.
48. Alderman MH, Madhavan S, Ooi WL, et al.: Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991, 324:1098-1104.
49. Campbell DJ, Woodward M, Chalmers JP, et al.: Prediction of myocardial infarction by N-terminal-pro-B-type natriuretic peptide, C-reactive protein, and renin in subjects with cerebrovascular disease. Circulation 2005, 112:110-116.
50. Wang TJ, Gona P, Larson MG, et al.: Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006, 355:2631-2639.
51. Meade TW, Cooper JA, Peart WS: Plasma renin activity and ischemic heart disease. N Engl J Med 1993, 329:616-619.
52. McMurray JJV: Haemodynamic, neurohumoral, renal and ambulatory electrocardiographic effects of a new oral renin inhibitor in stable heart failure [abstract]. Presented at the European Society of Cardiology Meeting. Vienna, Austria; September 2007.
53. Saris JJ, t'Hoen PA, Garrelds IM, et al.: Prorenin induces intracellular signaling in cardiomyocytes independently of angiotensin II. Hypertension 2006, 48:564-571.
54. Moore N, Dicker P, O'Brien JK, et al.: Renin gene polymorphisms and haplotypes, blood pressure and responses to renin-angiotensin system inhibition. Hypertension 2007, 50:1-8.
55. Fuchs S, Philippe J, Germain S, et al.: Functionality of two new polymorphisms in the human renin gene enhancer region. J Hypertension 2002, 20:2391-2398.
56. Brown MJ: Renin: friend or foe? Heart 2007, 93:1026-1033.